Novartis43m
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
UC San Diego Today45m
Xylazine Detected in U.S.-Mexico Border Drug Supply, Study Finds
New study confirms the presence of xylazine on the U.S.-Mexico border, posing numerous health risks for people in the region.
The Manila Times49m
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...
Fierce Pharma2h
Alnylam's Amvuttra wins key approval in ATTR-CM, teeing up showdown with Pfizer
Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...
Targeted Oncology2h
FDA OKs TLX007-CDx in Prostate Cancer Treatment
TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages ...
BioSpace2h
Alnylam’s Amvuttra Approved as First RNAi Silencer for Rare Type of Cardiomyopathy
The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...
US FDA expands approval for Alnylam's drug to treat rare heart disease
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
A New Study Adds to the Evidence That Drug Busts Result in More Overdose Deaths
The researchers found that drug seizures in San Francisco were associated with a substantial increase in fatal opioid ...
Alnylam's Amvuttra Gets Approval for Expanded Indication From FDA
Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.
Researchers find clue to delay Alzheimer's symptoms. Now they have to prove it
An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in ...
BioPharma Dive3h
Alnylam drug gets long-awaited FDA approval in deadly heart disease
Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...
US FDA approves Alnylam's drug for rare heart condition
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...